IL17A and cancer: It is known that poor prognosis in cancer is associated with a great vascularization of primary tumor mass and that tumor cells secrete angiogenic factors, among which Interleukin 17 (IL-17) derived from CD4+ T-cells; Mifamurtide reduces, both directly and through macrophage activation, the expression of IL-17R in MG63 OS cell line [79].